Zymeworks Inc. has obtained IND clearance from the FDA for ZW-171, a novel T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers. Clinical development will begin this year, and additional applications will be filed in the second half of the year seeking trial clearances in other territories.
Sonnet Biotherapeutics Holdings Inc. has announced the generation and in vitro characterization of two novel drug candidates, SON-1411 (IL18BPR-FHAB-IL12) and SON-1400 (IL18BPR-FHAB), each containing a modified version of recombinant human interleukin (IL)-18 (IL-18 binding protein resistant [IL-18BPR]).
Bivictrix Therapeutics plc’s BVX-001, a first-in-class Bi-Cygni bispecific antibody-drug conjugate (ADC) for the treatment of acute myeloid leukemia (AML), has demonstrated a favorable toxicity profile in an industry standard toxicology model.
Hudson Therapeutics Inc., a U.S. subsidiary of Shaperon Inc., has announced the signing of a memorandum of understanding (MOU) between Shaperon and Dong-A ST Co. Ltd. for the development of nanobody-based new drugs.
Bright Peak Therapeutics Inc. has raised $90 million in a series C financing. Proceeds will be used to accelerate a pipeline of next-generation immunotherapies and advance BPT-567 into a phase I/IIa trial.
Calidi Biotherapeutics Inc. has conducted studies in animals to determine the safety and efficacy of oncolytic virotherapy (OV) with CLD-201 (Supernova-1) to treat solid tumors.
Calidi Biotherapeutics Inc. has announced a collaboration with Siga Technologies Inc. to support the development of Calidi’s systemic and targeted Rtnova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.
Researchers from the University of Science and Technology of China (USTC) reported data from a study that aimed to assess the effects of the highly selective telomerase inhibitor, BIBR-1532, on immune activation induced by radiotherapy (RT).
Odimma Therapeutics SAS has developed ODI-2001, a new biological from the combination of neoantigen-expressing DNA vector, an anti-CTLA-4 antibody and an attenuated poxvirus with the aim of increasing the immune response against tumors.
RSS
